NA
CUE icon

NewEdge Advisors’s Cue Biopharma CUE Stock Holding History

NewEdge Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-667
Closed -$4.6K – 4234
2026
Q1 		$4.6K Hold
667
– – ﹤0.01% 3618
2025
Q4 		$6.11K Hold
667
– – ﹤0.01% 3620
2025
Q3 		$14.4K Hold
667
– – ﹤0.01% 3236
2025
Q2 		$13.6K Buy
667
+582
+685% +$12.4K ﹤0.01% 3091
2025
Q1 		$2.32K Hold
85
– – ﹤0.01% 3478
2024
Q4 		$2.78K Hold
85
– – ﹤0.01% 3387
2024
Q3 		$1.93K Hold
85
– – ﹤0.01% 3388
2024
Q2 		$3.16K Buy
+85
New +$4.2K ﹤0.01% 3228

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

NewEdge Advisors's CUE Position: Q2 2026 in Review

NewEdge Advisors sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 667 shares — an estimated $4.6K sold.

NewEdge Advisors first reported a position in CUE in Q2 2024 and held it in 8 quarters. The position peaked at $14.4K in Q3 2025. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • NewEdge Advisors reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
  • NewEdge Advisors sold 667 Cue Biopharma shares in Q2 2026, an estimated $4.6K.
  • NewEdge Advisors first reported a position in Cue Biopharma in Q2 2024 and held it in 8 quarters.
  • NewEdge Advisors's Cue Biopharma position peaked at $14.4K in Q3 2025.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.